ARQT
insider transactionsArcutis Biotherapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-40.9K
0 buy · 40.9K sell
Net value · 90d
-$968.8K
$0 in · $968.8K out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
12
0 buy · 40.9K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Director · 10b5-1
$16.3K
635 sh · $25.67
Own -2%
-
Sell·S
Director · 10b5-1
$120.6K
4.9K sh · $24.38
Own -15%
-
Exercise·M
Director · 10b5-1
$0
2.3K sh
Own +10%
-
Exercise·M
Director · 10b5-1
$0
1.0K sh
Own +10%
-
Exercise·M
Director · 10b5-1
$0
822 sh
Own +10%
-
Sell·S
Director · 10b5-1
$100.0K
4.1K sh · $24.41
Own -10%
-
Exercise·M
Director · 10b5-1
$19.5K
2.3K sh · $8.63
Own +6%
-
Exercise·M
Director · 10b5-1
$7.7K
1.0K sh · $7.51
Own +3%
-
Exercise·M
Director · 10b5-1
$5.4K
822 sh · $6.52
Own +2%
-
Grant·A
Director
$0
16.7K sh
Own New
-
Grant·A
Director
$0
5.8K sh
Own +22%
-
Grant·A
Director
$0
16.7K sh
Own New
-
Grant·A
Director
$0
5.8K sh
Own +22%
-
Grant·A
Director
$0
16.7K sh
Own New
-
Grant·A
Director
$0
5.8K sh
Own +18%
-
Grant·A
Director
$0
16.7K sh
Own New
-
Grant·A
Director
$0
5.8K sh
Own +26%
-
Grant·A
Director
$0
16.7K sh
Own New
-
Grant·A
Director
$0
5.8K sh
Own +33%
-
Grant·A
Director
$0
16.7K sh
Own New
-
Grant·A
Director
$0
5.8K sh
Own +144%
-
Grant·A
Director
$0
16.7K sh
Own New
-
Grant·A
Director
$0
5.8K sh
Own +26%
-
Grant·A
Director
$0
16.7K sh
Own New
-
Grant·A
Director
$0
5.8K sh
Own +26%
-
Sell·S
Latha Vairavan KEY
SVP Chief Financial Officer · 10b5-1
$9.2K
435 sh · $21.05
Own -1%
-
Sell·S
Reporting Person's Title: EVP… · 10b5-1
$4.7K
222 sh · $21.05
Own -0%
-
Sell·S
Latha Vairavan KEY
SVP Chief Financial Officer · 10b5-1
$31.7K
1.3K sh · $23.61
Own -2%
-
Sell·S
Todd Watanabe KEY
Reporting Person's title: Pre… · 10b5-1
$74.9K
3.2K sh · $23.61
Own -0%
-
Sell·S
Reporting Person's title: EVP… · 10b5-1
$20.9K
884 sh · $23.61
Own -1%
-
Sell·S
Reporting Person's title: EVP… · 10b5-1
$171.5K
7.4K sh · $23.27
Own -5%
-
Sell·S
Reporting Person's Title: EVP… · 10b5-1
$16.1K
684 sh · $23.61
Own -1%
-
Sell·S
Director · 10b5-1
$164.2K
7.1K sh · $22.99
Own -18%
-
Sell·S
Director · 10b5-1
$238.8K
10.0K sh · $23.88
Own -20%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Howard G. Welgus 10b5-1 | Sell S | 635 | $16.3K |
| Jun 15, 2026 | Sue-Jean Lin 10b5-1 | Sell S | 4.9K | $120.6K |
| Jun 15, 2026 | Howard G. Welgus 10b5-1 | Exercise M | 2.3K | $0 |
| Jun 15, 2026 | Howard G. Welgus 10b5-1 | Exercise M | 1.0K | $0 |
| Jun 15, 2026 | Howard G. Welgus 10b5-1 | Exercise M | 822 | $0 |
| Jun 15, 2026 | Howard G. Welgus 10b5-1 | Sell S | 4.1K | $100.0K |
| Jun 15, 2026 | Howard G. Welgus 10b5-1 | Exercise M | 2.3K | $19.5K |
| Jun 15, 2026 | Howard G. Welgus 10b5-1 | Exercise M | 1.0K | $7.7K |
| Jun 15, 2026 | Howard G. Welgus 10b5-1 | Exercise M | 822 | $5.4K |
| Jun 5, 2026 | Patrick J Heron | Grant A | 16.7K | $0 |
| Jun 5, 2026 | Patrick J Heron | Grant A | 5.8K | $0 |
| Jun 5, 2026 | Sue-Jean Lin | Grant A | 16.7K | $0 |
| Jun 5, 2026 | Sue-Jean Lin | Grant A | 5.8K | $0 |
| Jun 5, 2026 | Howard G. Welgus | Grant A | 16.7K | $0 |
| Jun 5, 2026 | Howard G. Welgus | Grant A | 5.8K | $0 |
| Jun 5, 2026 | Keith R Leonard | Grant A | 16.7K | $0 |
| Jun 5, 2026 | Keith R Leonard | Grant A | 5.8K | $0 |
| Jun 5, 2026 | Terrie Curran | Grant A | 16.7K | $0 |
| Jun 5, 2026 | Terrie Curran | Grant A | 5.8K | $0 |
| Jun 5, 2026 | Amit Munshi | Grant A | 16.7K | $0 |
| Jun 5, 2026 | Amit Munshi | Grant A | 5.8K | $0 |
| Jun 5, 2026 | Halley E Gilbert | Grant A | 16.7K | $0 |
| Jun 5, 2026 | Halley E Gilbert | Grant A | 5.8K | $0 |
| Jun 5, 2026 | Neha Krishnamohan | Grant A | 16.7K | $0 |
| Jun 5, 2026 | Neha Krishnamohan | Grant A | 5.8K | $0 |
| May 11, 2026 | Latha Vairavan KEY 10b5-1 | Sell S | 435 | $9.2K |
| May 11, 2026 | Patrick Burnett 10b5-1 | Sell S | 222 | $4.7K |
| May 4, 2026 | Latha Vairavan KEY 10b5-1 | Sell S | 1.3K | $31.7K |
| May 4, 2026 | Todd Watanabe KEY 10b5-1 | Sell S | 3.2K | $74.9K |
| May 4, 2026 | Masaru Matsuda 10b5-1 | Sell S | 884 | $20.9K |
| May 4, 2026 | Masaru Matsuda 10b5-1 | Sell S | 7.4K | $171.5K |
| May 4, 2026 | Patrick Burnett 10b5-1 | Sell S | 684 | $16.1K |
| May 1, 2026 | Howard G. Welgus 10b5-1 | Sell S | 7.1K | $164.2K |
| Apr 1, 2026 | Howard G. Welgus 10b5-1 | Sell S | 10.0K | $238.8K |
About ARQT insider trading
This page tracks insider transactions for Arcutis Biotherapeutics, Inc. (ARQT) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.